Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach

Edward Oliver, Dimitrios Kourouklis and Mireia Jofre-Bonet
Additional contact information
Edward Oliver: Adelphi Values
Dimitrios Kourouklis: CERNA i3 - Centre d'économie industrielle i3 - Mines Paris - PSL (École nationale supérieure des mines de Paris) - PSL - Université Paris Sciences et Lettres - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique, OHE - Office of Health Economics
Mireia Jofre-Bonet: OHE - Office of Health Economics, Department of Economics [University of London] - UCL - University College of London [London]

Post-Print from HAL

Date: 2024-10
References: Add references at CitEc
Citations:

Published in Research Policy, 2024, 53 (8), pp.105053. ⟨10.1016/j.respol.2024.105053⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04636417

DOI: 10.1016/j.respol.2024.105053

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().